Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

NCT07165847 is registered in ClinicalTrials.gov with Daping Hospital and the Research Institute of Surgery of the Third Military Medical University as lead sponsor.

NCT NCT07165847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07165847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Lead sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2025
Completion date
December 31, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer (gc), immunotherapy, neoadjuvant chemoimmunotherapy, neoadjuvant therapy, radiotherapy